A call for better reporting of trials using surrogate primary endpoints
Saved in:
| Main Authors: | Anthony Muchai Manyara, Oriana Ciani, Rod S. Taylor |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Online Access: | https://doi.org/10.1002/trc2.12340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Significance of biomarkers and surrogate endpoints in preclinical and clinical trials
by: Ilić Katarina, et al.
Published: (2007-01-01) -
Surrogate endpoints for neonatal outcome: A rapid review
by: Shiraz El Adam, et al.
Published: (2024-08-01) -
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
by: Charlotte Pawlyn, et al.
Published: (2024-08-01) -
Blood biomarkers as surrogate endpoints in Alzheimer’s disease research
by: Guogen Shan, et al.
Published: (2025-05-01) -
Surrogate endpoints in cost-effectiveness analysis for use in medical technology assessment
by: T. I. Busheva, et al.
Published: (2025-07-01)